Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,767.60
(
-1.51%
)
Dow Jones
46,225.15
(
-1.63%
)
Brent Oil
109.26
(
2.51%
)
Bitcoin
70,912.20
(
-0.46%
)
News Focus
News Focus
Post# of 257257
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122795
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: zipjet post# 134515

Friday, 01/06/2012 8:00:28 PM

Friday, January 06, 2012 8:00:28 PM

Post# of 257257

BIIB/ELN—He thinks that there will be switching to BG12, once approved, of patients on Tysabri that are JCV+ and who have been on drug for years.

That’s not exactly going out on a limb! The real question is what becomes of patients who are JCV-negative—hence my question in #msg-70615422.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now